Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 ADC January 7, 2025
Investigator-initiated trial (IIT) initiated in China for KJ-C2219 for the treatment of R/R B-NHL January 7, 2025
FDA Acceptance and Priority Review of NDA for Avutometinib + Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer Announced January 7, 2025
DATROWAY Approved in Japan for Patients with Previously Treated Unresectable or Recurrent HR+ve, HER2neg Breast Cancer January 7, 2025
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement January 7, 2025
BeiGene to acquire global development, manufacturing, and commercialization rights for an ADC from DualityBio January 7, 2025
NDA submitted to US FDA for Accelerated Approval for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma January 7, 2025
European Commission approves RYBREVANT (amivantamab) + LAZCLUZE (lazertinib) for the 1L treatment of patients with EGFR-mutated advanced NSCLC January 7, 2025
China’s NMPA Approves VYLOYTM (zolbetuximab) for 1L Treatment of Advanced Gastric or GEJ Adenocarcinoma January 7, 2025
